Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Infectious diseases, vaccines and treatments

Session: Poster Session A

(263) Human albumin for adults with sepsis: an updated systematic review and meta-analysis of randomized controlled trials

Monday, August 26, 2024
8:00 AM – 6:00 PM CEST
Location: Convention Hall II

    Presenting Author(s)

  • Zhaohui Bai, PhD

    Postdoctor
    Peking University Health Science Center
    Beijing, China (People's Republic)

    • Co-Author(s)

  • YL

    Yongjie Lai

    Peking University Health Science Center, China (People's Republic)

  • Yang Xu, PhD (he/him/his)

    Assistant Professor
    Peking University Health Science Center
    Beijing, China (People's Republic)

  • LS

    Luwen Shi

    Peking University Health Science Center, China (People's Republic)

  • XG

    Xiaodong Guan

    Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, China (People's Republic)

Background: Sepsis affects millions of people and imposes a substantial economic and social burden worldwide. However, the role of human albumin in the management of septic patients remains unclear.

Objectives: To clarify the effect of human albumin on the survival of septic patients.

Methods: EMBASE, PubMed, and Cochrane Library databases were searched. Randomized controlled trials (RCTs) regarding use of human albumin in septic patients were eligible. The overall, intensive care unit (ICU), in-hospital/28-day, and 90-day mortality were pooled, respectively. Subgroup analyses were performed according to target population, type and dose of human albumin, and type of control group. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.

Results: Twenty-four RCTs were finally included. Meta-analysis of all included RCTs showed that human albumin cannot decrease the overall (RR=1.02, 95%CI=0.96-1.07, P=0.56), ICU (RR=1.06, 95%CI=0.83-1.34, P=0.65), in-hospital/28-day (RR=1.01, 95%CI=0.96-1.07, P=0.68), and 90-day (RR=1.01, 95%CI=0.96-1.08, P=0.65) mortality of total patients. Subgroup analyses showed that human albumin cannot decrease the overall (RR=1.05, 95%CI=0.93-1.19, P=0.45), ICU (RR=1.12, 95%CI=0.69-1.83, P=0.64), in-hospital/28-day (RR=0.98, 95%CI=0.83-1.16, P=0.84), and 90-day (RR=1.19, 95%CI=0.98-1.43, P=0.08) mortality of sepsis patients and the overall (RR=0.98, 95%CI=0.93-1.04, P=0.57), ICU (RR=1.03, 95%CI=0.74-1.43, P=0.87), in-hospital/28-day (RR=1.01, 95%CI=0.94-1.09, P=0.74), and 90-day (RR=0.89, 95%CI=0.79-1.00, P=0.06) mortality of septic shock patients. Additionally, 20% human albumin (RR=0.89, 95%CI=0.80-0.99, P=0.03) and high daily dose of human albumin (RR=0.90, 95%CI=0.82-0.99, P=0.03) might benefit for the overall survival of patients with septic shock.

Conclusions: Based on the current evidence, general use of human albumin infusion to improve the survival of septic patients isn’t recommended.